22 results about "Prostate carcinoma" patented technology

The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), and therapy. More specifically, the present disclosure relates to novel compositions useful in imaging and treatment of conditions such as prostate cancer, somatostatin receptor-expressing tumors, like neuroendocrine tumor, epithelial tumors, as well as to methods wherein such compositions are prepared.

Provided are methods and compositions for enhancing radiotherapy in various cancers by administering dopamine receptor (DRD2)‐binding phenylpiperazine derivatives such as brexpiprazole, cariprazine, pipamperone, and perospirone. In vitro studies show that combining these agents with ionizing radiation (e.g., 5 Gy) significantly reduces cancer cell survival, suppresses metastatic and stemness markers (e.g., CD44, MMP‑2, Snail, Nanog), and promotes apoptosis. Fractionated or single‐fraction radiation regimens can be paired with DRD2 antagonists to lower treatment‐resistant phenotypes, decrease the likelihood of recurrence, and potentially reduce necessary radiation dosages. The approach applies to breast, prostate, lung, pancreatic, and brain cancers, among others. Depending on tumor characteristics, additional chemotherapeutic or immunotherapeutic agents may further improve outcomes.

The application provides a novel diagnostic marker for neuroendocrine prostate cancer and application thereof, and relates to the technical field of genetic engineering. The novel diagnostic marker is PCSK1N and / or C4orf48. The application overcomes the defects of the prior art, verifies the high expression of PCSK1N and / or C4orf48 in neuroendocrine prostate cancer, and based on this, the PCSK1N and / or C4orf48 can be used as a novel diagnostic marker for neuroendocrine prostate cancer.

The invention relates to a pharmaceutical composition of an extract of Agarophyton chilensis, with antiproliferative effect in prostate cancer, comprising(a) 0.1 to 90% of an oleoresin of Agarophyton chilensis, with the following major components: palmitic acid, arachidonic acid, oleic acid, stearic acid, meristic acid, linoleic acid; and(b) 10 to 99.9% excipients and formulation aids for different pharmaceutical forms.And its use to prepare a drug for the treatment or prevention of prostate cancer and other hyperproliferative states of prostate tissue cells.

The application discloses a kind of 1,5-diaryl-1,2,4-triazole compounds or pharmaceutically acceptable salt represented by structural formula I, II or pharmaceutical composition containing such compounds.The application also discloses the application of the compound or pharmaceutically acceptable salt in the preparation of drugs for treating various malignant tumors and related diseases of tumor metastasis.The compound represented by formula I, II of the application can inhibit the proliferation, invasion and infiltration of tumor cells such as gastric cancer cells, breast cancer cells, prostate cancer cells, colon cancer cells, liver cancer cells, non-small cell lung cancer cells and bladder cancer cells in a concentration gradient-dependent manner, has the characteristics of high efficiency and low toxicity, and has a wide application prospect in the biological medicine industry.

Provided herein are methods for treating autophagy dependent cancers. In particular, provided herein are methods for treating neuroendocrine prostate cancer (NEPC), pancreatic ductal adenocarcinoma (PDAC), pancreatic neuroendocrine tumors (PNETs), pancreatic neuroendocrine carcinomas (NECs), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC) comprising administering a therapeutic agent, e.g., ESK981, that inhibits PIKfyve and, optionally, a RAS inhibitor.

This invention discloses a CD33-blocking humanized antibody and its uses. The CD33-blocking humanized antibody comprises a heavy chain and a light chain; the heavy chain includes a variable region, the amino acid sequence of which is shown in SEQ ID NO. 20; the light chain includes a variable region, the amino acid sequence of which is shown in SEQ ID NO. 21. This invention also discloses a method for preparing the CD33-blocking humanized antibody, obtained by humanizing a rabbit CD33 antibody. Furthermore, it discloses the application of the CD33-blocking humanized antibody in the preparation of drugs for inhibiting liver metastasis of neuroendocrine prostate cancer and small cell lung cancer. The CD33-blocking humanized antibody of this invention exhibits high affinity and high specificity for CD33, and demonstrates excellent therapeutic and inhibitory effects on liver metastasis of neuroendocrine prostate cancer and small cell lung cancer.

The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.

The application belongs to the technical field of biological medicine, and particularly relates to a dipicolinate ester derivative and application thereof. The dipicolinate ester derivative has broad-spectrum antitumor activity, can significantly inhibit the proliferation activity of lung cancer cells, pancreatic cancer cells and prostate cancer cells, and has more excellent inhibitory activity on lung cancer cells, and can significantly inhibit the growth of mouse subcutaneous small cell lung cancer transplanted tumors. In addition, the dipicolinate ester derivative has no toxic effect on normal cells of the body, can be applied to preparation of anticancer drugs, and has broad application prospects in the aspect of anticancer.

Compounds of Formula (Ia)wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR′R′,Q is C(O), O, NR′, S, S(O)2, C(O)2 (CH2)pY is C(O), O, NR′, S, S(O)2, C(O)2, (CH2)pZ is H or C1-C4 alkyl,R′ is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted of unsubstituted when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition, Radiolabels can be incorporated into the structure through a variety of prosthetic, groups attached at the X amino acid side chain via a carbon or hetero atom linkage.

This disclosure relates to novel GSPT1 degraders and the use of novel GSPT1 degraders. More specifically, this disclosure relates to a compound represented by formula I, or its stereoisomer, hydrate, solvate, or pharmaceutically acceptable salt, a pharmaceutical composition containing the same for treating disorders of uncontrolled cell proliferation, and a method for treating disorders of uncontrolled cell proliferation by administering the same to a mammal. The compounds relating to this disclosure exhibit high selectivity and sustained degrading activity for GSPT1, excellent pH stability, and low cytotoxicity to normal cells, and therefore have excellent anticancer efficacy and a high therapeutic index. In addition, the compounds relating to this disclosure may exhibit excellent anticancer activity against cancers exhibiting a neuroendocrine phenotype, such as small cell lung cancer (SCLC), neuroendocrine pulmonary cancer (NEC), and neuroendocrine prostate cancer (NEPC).

The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), and therapy. More specifically, the present disclosure relates to novel compositions useful in imaging and treatment of conditions such as prostate cancer, somatostatin receptor-expressing tumors, like neuroendocrine tumor, epithelial tumors, as well as to methods wherein such compositions are prepared.

This invention discloses a PSA aptamer sensor based on a screen-printed electrode, its preparation, and detection method. In this invention, a composite material of AuNPs and graphene aerogel is used to modify the surface of a screen-printed electrode. The aptamer is modified onto the sensor by forming gold-sulfur (Au-S) bonds with a thiol-modified DNA single-stranded aptamer. Excess gold active sites are blocked with MCH to construct the PSA aptamer sensor. A certain concentration of PSA and UA is selected and incubated with the sensor. The EIS test method is used to detect PSA by recording its impedance changes, and the detection limit of the sensor is obtained. Utilizing the advantages of large-scale mass production and low cost of screen printing technology, combined with the excellent physical and electrical properties of nanomaterials, an electrochemical sensor for the detection of prostate-specific antigen (PSA) is prepared, enabling convenient, efficient, and low-cost detection, providing a new approach for prostate cancer patients to be detected outside of hospitals and laboratories.

The application discloses an engineered anti-PSMA-TAT@celinexor exosome for treating castration-resistant prostate cancer and a preparation method and application thereof. The exosome is constructed by gene engineering and chemical modification technology, and an anti-PSMA antibody fragment with prostate-specific membrane antigen targeting function and a cell-penetrating peptide TAT are co-displayed on the surface of the exosome, and an anticancer drug celinexor is efficiently loaded, so that a novel targeted drug delivery system is constructed. The system realizes the enrichment of the exosome in the prostate cancer tissue site by using anti-PSMA, and further realizes the double precise targeting from the tissue to the cell and then to the nucleus by the aid of the TAT peptide to promote the drug to penetrate the cell membrane and further target the nucleus. The strategy not only significantly enhances the accumulation and efficacy of celinexor in the nucleus of the prostate cancer, but also effectively reduces the toxic side effects of celinexor on normal tissues through the natural biocompatibility and targeted delivery characteristics of the exosome, thereby improving the treatment safety.

The present invention relates to quinoline compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X' ring A, ring B, R1, R2, R3, R4, R5, R6, R7, R8, 'm' and 'n' are as defined herein. The present invention also relates to quinoline compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and apoptosis by modulating protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to quinoline compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent associated diseases and conditions such as cancers like Thyroid carcinoma, Ovarian carcinoma, Pancreatic carcinoma, Prostatic carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast carcinoma, Colorectal carcinoma, Oral squamous cell carcinoma, Colorectal, Lung adenocarcinoma or Endometrial cancer.

The invention provides application of a compound in preparation of a medicine for inhibiting G3BPs, and belongs to the technical field of biological medicine. The medicine is used for treating tumors, neurodegenerative diseases or virus infection; the tumors comprise any one or a combination of lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, pancreatic cancer, cervical cancer, skin cancer, osteosarcoma, liposarcoma, smooth muscle sarcoma, leukemia, lymphoma, multiple myeloma, glioma, meningioma, testicular cancer, endometrial cancer, cervical cancer, ovarian cancer, melanoma, thyroid cancer, kidney cancer or bladder cancer. When the compound shown in the formula (I) is combined with different anti-tumor drugs in various tumor cells, the sensitivity of the cells to the anti-tumor drugs can be improved, so that the drug resistance of the tumor cells is reduced.

The invention discloses a preparation method of biodegradable alginate microspheres and a composition of the biodegradable alginate microspheres. The biodegradable alginate microspheres are used for treating at least one of the following diseases: hepatocellular carcinoma, colorectal hepatic metastasis, parangganglioma hepatic metastasis, neuroendocrine hepatic metastasis, gastrointestinal hepatic metastasis, mammary gland hepatic metastasis, melanoma hepatic metastasis, pancreatic hepatic metastasis, bile duct cancer hepatic metastasis, colorectal pulmonary metastasis and kidney pulmonary metastasis. Cirrhosis-associated thrombocytopenia, metastatic extrahepatic cholangiocarcinoma, glioblastoma, renal cell carcinoma, prostate cancer, and hysteromyoma. In some embodiments, the preparation method of the biodegradable alginate microspheres can utilize a microfluidic box.

The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), and therapy. More specifically, the present disclosure relates to novel compositions useful in imaging and treatment of conditions such as prostate cancer, somatostatin receptor-expressing tumors, like neuroendocrine tumor, epithelial tumors, as well as to methods wherein such compositions are prepared.

A prodrug nanoparticle for targeted accumulation and activation (treatment) in tumor tissue, that consists of a Pt(IV) complex with the following formula: wherein R1 und R2 are the same or different branched or unbranched alkyls having at least 14 carbon atoms, a sonosensitizer and a biocompatible drug delivery system can be used to treat tumors and in particular metastases in a way that is well tolerated by the body. The prodrug nanoparticles according to the invention are particularly suitable for the treatment of mammary carcinomas, pancreatic carcinomas, prostate carcinomas, bronchial carcinomas, endometrial carcinomas, germ cell tumors, non-Hodgkin's lymphomas and malignant mesotheliomas and, in particular, colorectal carcinomas, and their respective metastases.

The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission computerized tomography (SPECT), and therapy. More specifically, the present disclosure relates to novel compositions useful in imaging and treatment of conditions such as prostate cancer, somatostatin receptor-expressing tumors, like neuroendocrine tumor, epithelial tumors, as well as to methods wherein such compositions are prepared.

The present disclosure provides methods for treating or preventing neuroendocrine tumor formation in subjects diagnosed with TP53 and RBI deficient adenocarcinomas (e.g., lung or prostate adenocarcinomas) using XP01 inhibitors. Also disclosed herein are methods for preventing neuroendocrine tumor formation in subjects diagnosed with adenocarcinomas (e.g., TP53 and RBI deficient lung or prostate adenocarcinomas) using XP01 inhibitors in combination with androgen receptor (AR) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, or chemotherapeutic drugs.